Results 221 to 230 of about 9,837,347 (345)

A proteomic investigation of forebrain regeneration in the leopard gecko (Eublepharis macularius)

open access: yesDevelopmental Dynamics, EarlyView.
Our investigation reveals ontogenetic, injury‐ and regeneration‐associated proteomic changes in the leopard gecko forebrain. Abstract Background The ability to replace lost or damaged neurons following an injury is termed reactive neurogenesis. Although reactive neurogenesis has been reported in several lizard species, the molecular mechanisms ...
Alexandra I. Noble   +2 more
wiley   +1 more source

Red-Shifted Epac-Based FRET cAMP Sensors for All-Optical cAMP Control and Multiparameter Imaging. [PDF]

open access: yesCells
Kressmann T   +5 more
europepmc   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

open access: yesEpilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer   +7 more
wiley   +1 more source

The anti-inflammatory efficacy of melanocortin drugs is influenced by genetic variation at MC1R. [PDF]

open access: yesSci Rep
Khodeneva N   +4 more
europepmc   +1 more source

Epilepsy‐associated SCN2A‐L1342P mutation drives network hyperexcitability and widespread transcriptomic changes in human cortical organoids

open access: yesEpilepsia, EarlyView.
Abstract Objective SCN2A pathogenic mutations, such as the recurrent heterozygous Nav1.2‐L1342P, are monogenic causes of epilepsy. In this human‐induced pluripotent stem cell–derived model system, we aim to investigate the molecular and cellular mechanisms underlying SCN2A‐L1342P‐associated pathology. Methods Using a human male induced pluripotent stem
Maria I. Olivero‐Acosta   +26 more
wiley   +1 more source

Potent and biased agonists of class B1 GPCRs from a heterochiral design strategy. [PDF]

open access: yesNat Chem
Gibadullin R   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy